Adamas spikes on results of PD study

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) gained $13.99 (83%) to $30.85 on Wednesday after it said once-daily 340 mg amantadine HCl ( ADS-5102) met the primary endpoint of the Phase III EASE LID study to treat levodopa-induced dyskinesia in Parkinson's disease patients. The compound significantly reduced levodopa-induced dyskinesia (LID) by 23% compared with placebo at 12 weeks, as assessed by the Unified Dyskinesia Rating Scale (UDysRS; p=0.0009).

The company said the reduction in LID was maintained at 24 weeks as well (p=0.0008), a secondary endpoint. The oral extended-release formulation of amantadine also met the primary endpoint of improving LID vs. placebo as measured by UDysRS at week eight in the Phase II/III EASED study in 2013 (p=0.005). ...